Q4 2024 Earnings Forecast for Bio-Rad Laboratories, Inc. Issued By Zacks Research (NYSE:BIO)

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Equities researchers at Zacks Research cut their Q4 2024 EPS estimates for shares of Bio-Rad Laboratories in a research note issued to investors on Monday, October 14th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $2.77 per share for the quarter, down from their prior forecast of $2.78. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $9.45 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q2 2025 earnings at $2.86 EPS, Q3 2025 earnings at $2.97 EPS and Q3 2026 earnings at $2.94 EPS.

Several other equities research analysts also recently commented on BIO. Wells Fargo & Company began coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 price objective for the company. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Thursday, August 1st. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $401.00 price objective on shares of Bio-Rad Laboratories in a research note on Friday, August 16th. Finally, Citigroup upgraded shares of Bio-Rad Laboratories from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $350.00 to $400.00 in a report on Tuesday, October 1st. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of "Moderate Buy" and an average target price of $368.20.

Bio-Rad Laboratories Stock Up 0.3 %

BIO stock traded up $1.10 during trading on Tuesday, reaching $342.16. 133,282 shares of the stock were exchanged, compared to its average volume of 251,352. The firm's 50 day moving average is $329.41 and its 200 day moving average is $306.82. The firm has a market cap of $9.76 billion, a P/E ratio of -33.03 and a beta of 0.95. The company has a current ratio of 6.28, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories has a twelve month low of $261.59 and a twelve month high of $364.24.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The medical research company reported $3.11 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.99. The firm had revenue of $638.50 million for the quarter, compared to analyst estimates of $645.79 million. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. The business's quarterly revenue was down 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.00 earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Capital Advisors Ltd. LLC grew its position in Bio-Rad Laboratories by 193.8% during the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock valued at $26,000 after buying an additional 62 shares during the period. UMB Bank n.a. boosted its stake in Bio-Rad Laboratories by 140.6% in the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Sound Income Strategies LLC bought a new position in shares of Bio-Rad Laboratories during the 1st quarter valued at approximately $38,000. EntryPoint Capital LLC purchased a new stake in shares of Bio-Rad Laboratories during the 1st quarter worth approximately $51,000. Finally, Headlands Technologies LLC bought a new stake in shares of Bio-Rad Laboratories in the 2nd quarter worth approximately $51,000. Institutional investors own 65.24% of the company's stock.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, COO Andrew J. Last sold 3,000 shares of the company's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares in the company, valued at $2,494,016.46. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares of the company's stock, valued at $2,494,016.46. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP James Barry sold 623 shares of the business's stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the transaction, the executive vice president now owns 147 shares in the company, valued at $48,582.03. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 17.06% of the company's stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.